ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "giant cell arteritis"

  • Abstract Number: 0766 • ACR Convergence 2023

    The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

    Valentin Sebastian Schäfer1, Tobias Schremmer2, Florian Recker3, Wolfgang Hartung4, Christina Duftner5, Sara Monti6, Alojzija Hocevar7, Rositsa Karalilova8, Annamaria Iagnocco9, PIERLUIGI MACCHIONI10, Giuseppe Antonio Germano11, Maria Esperanza Naredo Sanchez12, Eugenio De Miguel13, Luca Seitz14, Thomas Daikeler15, Markus Aschwanden16, Dennis Boumans17, Chetan Mukhtyar18, smith kate19, Richard Wakefield20, Andreas Diamantopoulos21, Stavros Chrysidis22, Berit Dalsgaard Nielsen23, Kresten Keller24, Uffe Dohn25, Lene Terslev26, Marcin Milchert27, Aaron Juche28, Wolfgang Schmidt29, George A. W. Bruyn30 and Christian Dejaco31, 1Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, 2Universitätsklinikum Bonn, Bonn, Germany, 3Department for Gynecology and Obstetrics, University Hospital Bonn, Bonn, Germany, 4Asklepios Clinic, Tegernheim, Germany, 5Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, 6Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 7Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, 8Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, 9University of Turin, Roma, Italy, 10Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 11Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, 12Rheumatology Department and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, 15Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, 16Department of Angiology, University Hospital Basel, Basel, Switzerland, 17Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, 18Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, 19NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 20s Leeds Insitute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 21Akershus University Hospital, Lørenskog, Norway, 22Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, 23Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, 24Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 25Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, 26Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 27Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, 28Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, 29Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, 30Reumakliniek Lelystad, Loenga, Netherlands, 31Azienda Sanitaria Alto Adige, Brunico, Italy

    Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). There is a need to develop training resources, because the glucocorticoid…
  • Abstract Number: 1882 • ACR Convergence 2023

    Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations

    Philipp Bosch1, Milena Bond2, Christian Dejaco3, Cristina Ponte4, Sarah Mackie5, Louise Falzon6, Wolfgang Schmidt7 and Sofia Ramiro8, 1Medical University of Graz, Graz, Austria, 2Azienda sanitaria dell'Alto Adige, Merano, Italy, 3Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, 4Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6University of Sheffield, Sheffield, United Kingdom, 7Immanuel Krankenhaus Berlin, Berlin, Germany, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…
  • Abstract Number: 2400 • ACR Convergence 2023

    Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept

    Jean-Paul Makhzoum1, Stephanie Ducharme-Benard2, Samer Hussein2, Rosalie-Selene Meunier2, Carolyn Ross3, Alik Chamlian4, Jonathan Ducharme5, Leia Chamlian4, Alae Dhahbi4, Christian Pagnoux6 and Remi Goupil7, 1Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Canadian Network for Research on Vasculitides, Montreal, QC, Canada, 2Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 3Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, 4Laval University, Montreal, QC, Canada, 5University of Sherbrooke, Montreal, QC, Canada, 6Mount Sinai Hospital, Toronto, ON, Canada, 7Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada

    Background/Purpose: Applanation tonometry (ATn) is a non-invasive, point-of-care tool used to capture arterial pressure waveforms. It can measure arterial pulse wave velocity (PWV), a marker…
  • Abstract Number: 2418 • ACR Convergence 2023

    Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4, Grainne Murphy5 and David Kane6, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Cork University Hospital, Cork, Ireland, 6Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
  • Abstract Number: 2603 • ACR Convergence 2023

    Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis

    Christopher Redmond1, Robert Zorc2, McKella Sylvester3, Cameron Rankin4, Rebecca Kuan5, Kristina Wells6, Lily Dai7, Kaitlin Quinn8, Massimo Gadina9 and Peter Grayson10, 1National Institutes of Health, Hagerstown, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, 3Colgate University, Bethesda, MD, 4NIAMS, NIH, Washington, DC, 5NIH, Bethesda, MD, 6University of California Davis, Bethesda, MD, 7NIH, Germantown, MD, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 10National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

    Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
  • Abstract Number: 0459 • ACR Convergence 2022

    The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study

    Hampus Henningson1, Björn Hammar2, Carl Turesson3 and Aladdin Mohammad1, 1Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 2Ophthalmology, Department of Clinical Sciences, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the age-group 50 years and older. Cranial involvement is common and can lead to…
  • Abstract Number: 0476 • ACR Convergence 2022

    Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High

    Andrea Hemmig1, Markus Aschwanden2, Sabine Seiler1, Christoph Berger3, Philipp Köhn1, Noemi Mensch1, Daniel Staub2, Mihaela Stegert1, Stephan Imfeld2 and Thomas Daikeler1, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, 2Department of Angiology, University Hospital Basel, Basel, Switzerland, 3Departments of Dermatology, Rheumatology and Internal Medicine, University Center for Immunology, University Hospital Basel, Basel, Switzerland

    Background/Purpose: Permanent vision loss (PVL) remains the most feared complication of giant cell arteritis (GCA). In recent years, fast track clinic approaches for early GCA…
  • Abstract Number: 0492 • ACR Convergence 2022

    Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study

    Ehizogie Edigin1, Amy Trang2, Solomon Anighoro3, Chinenye Osuorji4, Precious Eseaton5, Osahon Idolor6, Christopher Hino1, Nneka Chukwu7 and Mehrnaz Hojjati1, 1Loma Linda University Health, Loma Linda, CA, 2Rush University Medical Center, Chicago, IL, 3St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, 4Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, 5University of South Wales, Cardiff, Wales, United Kingdom, 6Piedmont Athens Regional, Atlanta, GA, 7Nuvance Health, Poughkeepsie

    Background/Purpose: Giant Cell Arteritis (GCA) is the most common vasculitis in patients more than 50 years of age in the western countries. Although corticosteroids remain…
  • Abstract Number: 1618 • ACR Convergence 2022

    Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Monitoring of Giant Cell Arteritis

    Rennie Rhee, Shubhasree Banerjee, Vatsal Bhatt, Madhura Tamhankar, Quy Cao, Naomi Amudala, Sherry Chou, Morgan Burke, Laurie Loevner, Peter Merkel and Jae Song, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In giant cell arteritis (GCA), there is a critical need to identify patients at risk for vision loss ("ocular GCA"). MRI evaluates neurovascular anatomy…
  • Abstract Number: 0460 • ACR Convergence 2022

    Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

    Naomi Patel1, Xiaoqing Fu2, yuqing zhang3 and John Stone4, 1Massachusetts General Hospital, Sale Creek, TN, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
  • Abstract Number: 0477 • ACR Convergence 2022

    Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?

    Hubert De Boysson1, Anael DUMONT2, Samuel DESHAYES2, Alexandre Nguyen2 and Achille Aouba1, 1Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 2Caen University Hospital, Caen, France

    Background/Purpose: We analyzed whether the use of beta-blockers in addition to conventional care in patients with Giant cell arteritis (GCA) and large vessel vasculitis (LVV)…
  • Abstract Number: 0493 • ACR Convergence 2022

    MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center

    Matthias Froehlich1, Thorsten A. Bley2, Marc Schmalzing3, Michael Gernert1, Rudolf A. Werner4, Jost Hillenkamp5, Karl Georg Haeusler6 and Konstanze V. Guggenberger2, 1University Hospital Wuerzburg, Dpt. of Internal Medicine II, Wuerzburg, Germany, 2University Hospital Wuerzburg, Dpt. of Radiology, Wuerzburg, Germany, 3University Hospital Wuerzburg, Wuerzburg, Germany, 4University Hospital Wuerzburg, Dpt. of Nuclear medicine, Wuerzburg, Germany, 5University Hospital Wuerzburg, Dpt. of Ophtalmology, Wuerzburg, Germany, 6University Hospital Wuerzburg, Dpt. of Neurology, Wuerzburg, Germany

    Background/Purpose: Imaging techniques for the detection of mural inflammation are cornerstones in the diagnosis of giant cell arteritis (GCA). Magnetic resonance imaging (MRI) and ultrasound…
  • Abstract Number: 1619 • ACR Convergence 2022

    Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities

    Eugenio De Miguel1, PIERLUIGI MACCHIONI2, Edoardo Conticini3, Corrado Campochiaro4, Rositsa Karalilova5, Sara Monti6, Cristina Ponte7, Giulia Klinowski2, Irene Monjo8, Paolo Paolo Falsetti3, Anastas Batalov9, alessandro tomelleri4 and Alojzija Hocevar10, 1Hospital Universitario La Paz, Madrid, Spain, 2IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 3Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, 4IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 7Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, 8Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 9Medical University of Plovdiv, Plovdiv, Bulgaria, 10University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of patients with GCA. In a…
  • Abstract Number: 0461 • ACR Convergence 2022

    The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis

    Naomi Patel1, Veronica Tozzo2, John Higgins2 and John Stone3, 1Massachusetts General Hospital, Sale Creek, TN, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…
  • Abstract Number: 0478 • ACR Convergence 2022

    Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR

    Colm Kirby1, Rachael Flood1, Ronan Mullan1, Grainne Murphy2 and David Kane1, 1Tallaght University Hospital, Dublin, Ireland, 2Cork University Hospital, Cork, Ireland

    Background/Purpose: It has been reported that 20-50% of patients with PMR have subclinical GCA. The natural history of US-defined subclinical GCA in PMR is not…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 36
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology